文献速递急性肾损伤慢性肾脏病肾小球疾病

慢性粒单核细胞白血病伴溶菌酶肾病及肾脏浸润提示疾病严重标志

Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease.
PubMed 文献 · Kidney Int Rep · 2023-09-07

这项法国和美国15中心回顾性研究纳入16例慢性粒单核细胞白血病(CMML)伴肾脏受累患者,中位年龄76.5岁,肾脏病诊断距CMML诊断中位6个月。肾活检主要病理为溶菌酶肾病(56%)和CMML肾脏浸润(37.5%)。与116例CMML对照相比,肾脏受累者单核细胞计数更高、更易进展为急性髓系白血病,但两组生存无差异。

要点

  • CMML患者出现蛋白尿或肾功能异常时应警惕溶菌酶肾病或肾脏浸润。
  • 肾活检有助于明确CMML相关肾损害的病理类型。
  • CMML伴肾脏受累者单核细胞更高、更易进展为AML,需密切监测。

核心结论

  • CMML患者肾脏受累最常见的两种病理类型为溶菌酶肾病和CMML肾脏浸润。
  • CMML伴肾脏受累者单核细胞计数更高、更易进展为AML,但生存与无肾脏受累者无差异。

研究设计与样本

  • 法国和美国15中心回顾性研究,纳入16例CMML伴急性肾损伤、慢性肾脏病或尿液异常的患者。
  • 对照组为116例CMML无肾脏受累患者。

主要发现

  • 16例患者中男性14例,中位年龄76.5岁(71.9-83),肾脏病诊断距CMML诊断中位6个月(1.6-25.6)。
  • 肾脏病诊断时中位尿蛋白肌酐比2 g/g(1.25-3.4),中位血肌酐2.26 mg/dl(1.46-2.68)。
  • 14例(87.5%)接受肾活检,主要病理为溶菌酶肾病(56%)和CMML肾脏浸润(37.5%)。
  • 中位随访15个月(9.9-34.9),4例为CKD 3期、4例CKD 4期、1例终末期肾病;2例进展为AML,5例死亡。
  • 与116例对照相比,肾脏受累者单核细胞计数更高(P < 0.001)、CMML-1更多(P = 0.005)、更易进展为AML(P = 0.02)、更常接受羟基脲或去甲基化药物治疗(P < 0.001),但生存无差异(P = 0.6978)。

临床怎么用

  • CMML患者应密切监测肾功能和尿液异常,以及时发现肾脏受累。
  • 对CMML伴肾脏损害者,肾活检可帮助鉴别溶菌酶肾病与肾脏浸润。
  • CMML伴肾脏受累提示更高AML转化风险,需加强血液学随访。

局限性

  • 回顾性研究,样本量小(16例肾脏受累患者)。
  • 部分患者肾脏功能监测数据不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic myelomonocytic leukemia (CMML) is a hematologic disorder that is an overlap syndrome between myelodysplastic syndromes and myeloproliferative neoplasms, and can be associated with autoimmune and inflammatory diseases. This study aimed to describe kidney involvement in patients with CMML, their treatments, and outcomes. METHODS: We conducted a French and American multicenter retrospective study in 15 centers, identifying patients with CMML with acute kidney injury (AKI), chronic kidney disease (CKD), and urine abnormalities. RESULTS: Sixteen patients (males, n = 14; median age 76.5 years [71.9-83]) developed a kidney disease 6 months [1.6-25.6] after the diagnosis of CMML. At the time of kidney disease diagnosis, median urinary protein-to-creatinine ratio was 2 g/g [1.25-3.4], and median serum creatinine was 2.26 mg/dl [1.46-2.68]. Fourteen patients (87.5%) underwent a kidney biopsy, and the 2 main pathological findings were lysozyme nephropathy (56%) and renal infiltration by the CMML (37.5%). Ten patients received a new treatment following the CMML-associated kidney injury. Among patients with monitored kidney function, and after a median follow-up of 15 months [9.9-34.9], 4 patients had CKD stage 3, 4 had CKD stage 4, 1 had an end-stage kidney disease. In our patient series, 2 patients evolved to an acute myeloid leukemia (AML), and 5 died. Compared with 116 CMML controls, patients who had a kidney involvement had a higher monocyte count (P < 0.001), had more CMML-1 (P = 0.005), were more susceptible to develop an AML (P = 0.02), and were more eligible to receive a specific hematologic treatment, with hydroxyurea, or hypomethylating agents (P < 0.001), but no survival difference was seen between the 2 groups (P = 0.6978). CONCLUSION: In this cohort of patients with CMML with a kidney injury, the 2 most frequent renal complications were lysozyme-induced nephropathy and renal infiltration by the CMML. Kidney involvement should be closely monitored in patients with CMML.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lafargue MC, Bobot M, Rennke HG, et al. Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease. Kidney Int Rep. 2023. PMID: 38106568. doi:10.1016/j.ekir.2023.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。